Clinical Efficacy of Biosimilar Switch of Adalimumab for Management of Uveitis-Reference-Cited by-同舟云学术

Clinical Efficacy of Biosimilar Switch of Adalimumab for Management of Uveitis

Author:

Murray GM¹,Griffith N²,Sinnappurajar P¹,Al Julandani DA¹,Clarke SLN¹³,Hawley DP⁴,Choi J²⁴,Guly CM⁵,Ramanan Athimalaipet V¹⁶

Affiliation:

1. Department of Rheumatology, Bristol Royal Hospital for Children, Bristol, UK

2. Department of Ophthalmology Sheffield Teaching Hospital NHS Foundation Trust, Sheffield, UK

3. MRC Integrative Epidemiology Unit and School of Population Health Sciences, University of Bristol, Bristol, UK

4. Department of Rheumatology Sheffield Children’s NHS Foundation Trust, Sheffield, UK

5. Department of Ophthalmology University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK

6. Bristol Medical School: Translational Health Sciences, University of Bristol, Bristol, UK

Funder

Wellcome Trust

Publisher

Informa UK Limited

Subject

Ophthalmology,Immunology and Allergy

Link

Reference23 articles.

4. Davio K. 2018. Accessed 2021 October 10. https://www.centerforbiosimilars.com/view/nhs-prepares-for-october-2018-arrival-of-biosimilar-adalimumab.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献